Agent Capital

TRexBio is a biotechnology company that leverages cutting-edge computational biology tools, a focus on human tissue, and expertise in immunobiology to develop therapeutics for cancer and inflammatory diseases. Its 'deep biology' discovery engine maps human tissue Treg behavior to disease processes, identifying and characterizing novel targets for therapeutic intervention. The platform supports the development of a portfolio of therapies that modulate the immune system to restore tissue immune homeostasis.

Foresight Diagnostics specializes in developing innovative liquid biopsy tests aimed at measuring minimal residual disease, which assists in patient management for cancer care. The company’s technology enables early cancer detection through a simple blood sample, utilizing the unique biological characteristics that differentiate cancer cells from healthy cells. This approach allows healthcare professionals to identify smaller tumors earlier and implement personalized treatment strategies tailored to individual patients. Foresight Diagnostics has attracted considerable interest from multiple pharmaceutical companies in the oncology sector, indicating a strong potential for collaboration and advancement in cancer diagnosis and treatment.

Cerevance LLC is a biotechnology company focused on developing innovative therapeutics for neurological and psychiatric disorders, including Alzheimer's disease, Parkinson's disease, and other chronic neurodegenerative conditions. Founded in 2016 and headquartered in Boston, Massachusetts, with an additional office in Cambridge, United Kingdom, the company utilizes its NETSseq platform to profile specific brain cell types, including neurons and glial cells, using a repository of over 15,000 human brain tissue samples. This platform provides detailed expression and epigenetic data, allowing Cerevance to identify promising therapeutic targets for central nervous system diseases. Through its research, the company aims to advance new medicines that can potentially address the underlying mechanisms of these debilitating conditions.

Cantai Therapeutics operates as a developer of drug candidates.

ViTToria Biotherapeutics specializes in developing gene-edited cell therapies, focusing on next-generation T-cell therapeutics that aim to address significant unmet medical needs. The company’s proprietary Senza5 Technology enhances the efficacy, safety, and utility of these cell-based treatments in preclinical settings. By improving dosing requirements, simplifying preconditioning regimens, minimizing manufacturing failures, and reducing the time from production to patient administration, ViTToria Biotherapeutics enables healthcare providers to achieve better patient outcomes. The innovative approach of the company positions it as a leader in the evolving field of cell therapies.

Jana Care, Inc. is a Boston-based company that specializes in mobile point-of-care diagnostic solutions aimed at screening, managing, and monitoring chronic diseases. The company developed the Aina Device, a self-monitoring tool for patients to use at home, and the Aina Station, designed for clinics and hospitals. These devices enable a variety of tests, including blood glucose, HbA1c, lipid profiles, creatinine, and hemoglobin assessments. Additionally, Jana Care offers The Habits Program, a twelve-week digital coaching initiative for individuals managing diabetes and pre-diabetes. Founded in 2011, the company also has an office in Bengaluru, India, and emerged from a project initiated to create a smartphone app for health workers to screen for oral cancer and cardiovascular disease in rural communities.

Foresight Diagnostics specializes in developing innovative liquid biopsy tests aimed at measuring minimal residual disease, which assists in patient management for cancer care. The company’s technology enables early cancer detection through a simple blood sample, utilizing the unique biological characteristics that differentiate cancer cells from healthy cells. This approach allows healthcare professionals to identify smaller tumors earlier and implement personalized treatment strategies tailored to individual patients. Foresight Diagnostics has attracted considerable interest from multiple pharmaceutical companies in the oncology sector, indicating a strong potential for collaboration and advancement in cancer diagnosis and treatment.

Palvella Therapeutics, based in Wayne, Pennsylvania, is a clinical-stage biopharmaceutical company established in 2015. It focuses on developing and commercializing targeted therapies for serious and rare genetic skin diseases, specifically genodermatoses. The company's lead product, QTORIN, is a specialized anhydrous gel designed to deliver active ingredients effectively into the skin, addressing the underlying causes of various dermatological conditions. Palvella's pipeline includes candidates aimed at treating microcystic lymphatic malformations and cutaneous venous malformations, utilizing its proprietary QTORIN platform to offer innovative solutions for underserved patient populations.

Carisma Therapeutics is a clinical-stage biotech company specializing in innovative chimeric antigen receptor macrophage technology to address solid tumors. Its proprietary platform focuses on engineering macrophages and monocytes, a type of myeloid cell, to develop advanced immunotherapies for cancer and other serious diseases. By harnessing the capabilities of these engineered cells, Carisma aims to enhance cellular immunotherapy and improve treatment outcomes for patients with solid tumors. The company's approach enables targeted therapeutic applications, positioning it at the forefront of cancer treatment development.

Carbon Biosciences focuses on developing genetic medicines to address serious diseases. The company utilizes a proprietary platform that employs novel parvoviruses, which are designed to target specific tissues and carry larger therapeutic cargo. This approach minimizes the risk of neutralizing immunity and allows for repeat dosing, making it particularly effective for conditions such as cystic fibrosis, where targeting lung and upper airway tissues is crucial. By leveraging industrial-scale viral production platforms, Carbon Biosciences aims to extend the reach of gene therapies, offering innovative solutions for researchers and patients alike.

ViTToria Biotherapeutics specializes in developing gene-edited cell therapies, focusing on next-generation T-cell therapeutics that aim to address significant unmet medical needs. The company’s proprietary Senza5 Technology enhances the efficacy, safety, and utility of these cell-based treatments in preclinical settings. By improving dosing requirements, simplifying preconditioning regimens, minimizing manufacturing failures, and reducing the time from production to patient administration, ViTToria Biotherapeutics enables healthcare providers to achieve better patient outcomes. The innovative approach of the company positions it as a leader in the evolving field of cell therapies.

Affini-T Therapeutics is a biotechnology company developing T-cell therapies for patients suffering from cancer. Affini-T uses a validated platform to select high-affinity T cell receptors specific to oncogenic mutations to pioneer cutting-edge solid tumor therapies. Affini-T leverages gene editing and synthetic biology to engineer novel T-cell therapies designed to eradicate tumors.

Cyrus Biotechnology, Inc. specializes in developing software tools for protein structure prediction and design, aiming to enhance research in biotechnology and pharmaceuticals. The company's flagship product, Rosetta, allows for the design of biologically active proteins that can address critical health issues, such as brain cancer treatment and gluten breakdown in Celiac Disease patients. Additionally, Cyrus Bench offers an enterprise version of the Rosetta toolkit, equipped with a variety of bio-molecular computation tools. The company also provides Cyrus CryoEM services, which include advanced structure refinement and model building. Founded in 2014 and headquartered in Seattle, Washington, Cyrus Biotechnology serves a diverse clientele, including pharmaceutical companies, venture-backed startups, and mid-sized biotech firms focused on therapeutic discovery and industrial biotechnology innovation.

Mediar Therapeutics is a pre-clinical stage biotechnology company based in Cambridge, Massachusetts, focused on developing antibody-based therapeutics for the treatment of fibrosis. Founded in 2019, the company aims to provide innovative solutions by targeting key fibrotic mediator proteins that contribute to the development of fibrosis in chronically damaged organs. Through its research and development efforts, Mediar seeks to enable medical practitioners to halt and potentially reverse critical fibrosis and related conditions, addressing a significant unmet need in the field of fibrotic diseases.

Carisma Therapeutics is a clinical-stage biotech company specializing in innovative chimeric antigen receptor macrophage technology to address solid tumors. Its proprietary platform focuses on engineering macrophages and monocytes, a type of myeloid cell, to develop advanced immunotherapies for cancer and other serious diseases. By harnessing the capabilities of these engineered cells, Carisma aims to enhance cellular immunotherapy and improve treatment outcomes for patients with solid tumors. The company's approach enables targeted therapeutic applications, positioning it at the forefront of cancer treatment development.

Carisma Therapeutics is a clinical-stage biotech company specializing in innovative chimeric antigen receptor macrophage technology to address solid tumors. Its proprietary platform focuses on engineering macrophages and monocytes, a type of myeloid cell, to develop advanced immunotherapies for cancer and other serious diseases. By harnessing the capabilities of these engineered cells, Carisma aims to enhance cellular immunotherapy and improve treatment outcomes for patients with solid tumors. The company's approach enables targeted therapeutic applications, positioning it at the forefront of cancer treatment development.

Metagenomi, Inc. is a biotechnology company focused on developing gene editing systems aimed at treating genetic diseases. Founded in 2016 and based in Emeryville, California, Metagenomi utilizes metagenomics and machine learning to uncover novel genome editing technologies derived from previously uncharacterized organisms. The company's innovative discovery platform enables the creation of highly efficient and specific gene editing tools, including programmable nucleases, base editors, and advanced integration systems such as prime editing and CRISPR-associated transposases. By harnessing these naturally evolved systems, Metagenomi seeks to address a wide range of genetic mutations that traditional genome engineering approaches have struggled to target, with the ultimate goal of providing transformative therapies for patients globally.

Palvella Therapeutics, based in Wayne, Pennsylvania, is a clinical-stage biopharmaceutical company established in 2015. It focuses on developing and commercializing targeted therapies for serious and rare genetic skin diseases, specifically genodermatoses. The company's lead product, QTORIN, is a specialized anhydrous gel designed to deliver active ingredients effectively into the skin, addressing the underlying causes of various dermatological conditions. Palvella's pipeline includes candidates aimed at treating microcystic lymphatic malformations and cutaneous venous malformations, utilizing its proprietary QTORIN platform to offer innovative solutions for underserved patient populations.

Interius BioTherapeutics is a biopharmaceutical company that develops in vivo cell-specific gene medicines to treat B cell lymphomas. Intravenous in vivo CAR treatment, which treats B cell lymphomas, is the company's flagship program. Its unique engineering provides exceptional target tissue specificity. The business is working on a second initiative to address autoimmune conditions. With the help of Interius, a novel and distinct therapeutic modality for the precise administration of gene therapies may soon be made available to patients in expanded care settings, without the need for preconditioning chemotherapy.

ImCheck Therapeutics is a developer of immuno-modulatory antibodies designed for the treatment of cancer and other immune-related diseases. The company's services are engaged in the discovery and development of immunomodulators for treating breast cancer, gastric, ovarian cancer cells and other solid solid tumours.

Metagenomi, Inc. is a biotechnology company focused on developing gene editing systems aimed at treating genetic diseases. Founded in 2016 and based in Emeryville, California, Metagenomi utilizes metagenomics and machine learning to uncover novel genome editing technologies derived from previously uncharacterized organisms. The company's innovative discovery platform enables the creation of highly efficient and specific gene editing tools, including programmable nucleases, base editors, and advanced integration systems such as prime editing and CRISPR-associated transposases. By harnessing these naturally evolved systems, Metagenomi seeks to address a wide range of genetic mutations that traditional genome engineering approaches have struggled to target, with the ultimate goal of providing transformative therapies for patients globally.

Pyxis Oncology is a developer of antibody therapeutics intended to promote the body's immune response to cancer. The company has engaged in deep analyses of tumor antigen-specific tumor-infiltrating lymphocytes (TILs) within hot tumors and of tumor cell signaling pathways within cold tumors, providing laboratories with development of novel antibody-based immunotherapies. It was founded in 2019 and is based in Boston, Massachusetts.

Entrada Therapeutics, Inc. is a biotechnology company focused on treating diseases through the intracellular delivery of biologics, such as proteins, peptides, and nucleic acids. Founded in 2016 and based in Boston, Massachusetts, the company aims to transform patient care by developing a new class of medicines that target intracellular mechanisms previously deemed inaccessible. Entrada's technology addresses challenges associated with delivering both large and small molecules, significantly enhancing the efficiency of therapeutic delivery into the cytosol. Its pipeline includes innovative therapies for neuromuscular diseases and other conditions, utilizing proprietary Endosomal Escape Vehicle (EEV) therapeutics to improve treatment outcomes across various organs and tissues.

Verge Genomics is a biotechnology company focused on transforming drug discovery for neurodegenerative diseases through the application of artificial intelligence. Founded by experts in machine learning and seasoned drug developers in neuroscience, the company aims to leverage advances in computational genomics and insights into brain science to identify promising therapeutic targets. Its drug discovery platform utilizes machine learning algorithms to analyze large datasets, enabling the identification of effective drugs and accelerating the development of life-saving treatments. By improving the efficiency of the drug development process, Verge Genomics seeks to enhance patient outcomes and reduce the overall costs associated with pharmaceutical development.

Pliant Therapeutics is a clinical stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis. Pliant's lead product candidate, PLN-74809, is an oral small-molecule dual selective inhibitor of avß6 and avß1 integrins that it is developing for the treatment of idiopathic pulmonary fibrosis, or IPF, and primary sclerosing cholangitis, or PSC. PLN-74809 has received Orphan Drug Designation from the U.S. Food and Drug Administration for both IPF and PSC. Pliant is currently recruiting two Phase 2a trials of PLN-74809 for the treatment of IPF and plans to initiate a Phase 2a trial in PSC in the second half of 2020. Pliant's second product candidate, PLN-1474, is a small-molecule selective inhibitor of avß1 for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis, or NASH, which Pliant has partnered with Novartis. PLN-1474 is currently undergoing a Phase 1 trial. In addition to clinical stage programs, Pliant currently has two preclinical programs targeting oncology and muscular dystrophies.

Carisma Therapeutics is a clinical-stage biotech company specializing in innovative chimeric antigen receptor macrophage technology to address solid tumors. Its proprietary platform focuses on engineering macrophages and monocytes, a type of myeloid cell, to develop advanced immunotherapies for cancer and other serious diseases. By harnessing the capabilities of these engineered cells, Carisma aims to enhance cellular immunotherapy and improve treatment outcomes for patients with solid tumors. The company's approach enables targeted therapeutic applications, positioning it at the forefront of cancer treatment development.

Skyhawk Therapeutics is a provvider of small molecule therapeutics designed to offer therapies that correct RNA expression.The company's therapeutics use proprietary technology that helps the rational design of small molecules that target specific binding pocket regions on RNA, using both sequence and structural specificity, at particular moments in the RNA splicing process, enabling physicians to target diseases driven by a type of RNA mis-splicing called exon skipping.

Hinge Bio is a biotechnology company that specializes in leveraging its proprietary Flex-Hinge antibody platform to develop bispecific and multispecific antibodies. It features chemical ligation process technology that enables the production of therapeutic candidates with orders-of-magnitude improved affinity and specificity. The company was founded in 2015 and headquartered in Burlingame, California.

Orchard Therapeutics is a biopharmaceutical company based in the United Kingdom that specializes in developing innovative gene therapies for serious and life-threatening rare diseases. The company employs an autologous ex vivo gene therapy approach, which modifies a patient's own hematopoietic stem cells to create a targeted treatment administered in a single dose. Orchard's portfolio includes Strimvelis, the first autologous gene therapy approved by the European Medicines Agency for the treatment of adenosine deaminase-severe combined immunodeficiency (ADA-SCID). Additionally, it is advancing clinical programs for various conditions, including metachromatic leukodystrophy, Wiskott-Aldrich syndrome, X-linked chronic granulomatous disease, and transfusion-dependent beta-thalassemia. The company also has an extensive preclinical pipeline targeting mucopolysaccharidosis types I, IIIA, and IIIB. Orchard Therapeutics collaborates with leading institutions in gene therapy research, enhancing its efforts to transform the lives of patients with rare diseases in the UK, European Union, and the United States. Founded in 2015 and headquartered in London, it aims to provide sustainable clinical benefits through its innovative therapies.

Orbus Therapeutics, Inc. is a biopharmaceutical company based in Palo Alto, California, established in 2012. The company specializes in the development and commercialization of therapies aimed at treating brain cancers and other rare diseases. Its primary product, Eflornithine, is an orally bioavailable small molecule that acts as a cytostatic agent, specifically targeting recurrent anaplastic astrocytoma, a rare form of central nervous system cancer. Orbus Therapeutics is dedicated to improving health outcomes for patients with life-threatening conditions by developing innovative medicinal products that inhibit tumor growth through the irreversible inhibition of the enzyme ornithine decarboxylase (ODC). The company is actively working on bringing Eflornithine to the North American market.

Dragonfly Therapeutics, Inc. is a clinical-stage biotechnology company based in Waltham, Massachusetts, focused on developing innovative therapeutics that activate immune responses against cancer. Utilizing its TriNKET platform, the company creates first-in-class drugs that target natural killer cells and other components of the innate immune system, effectively addressing immune suppressive factors within the tumor microenvironment. These novel therapies aim to enhance anti-cancer immune responses both as standalone treatments and in combination with existing cancer immunotherapies. Founded in 2015, Dragonfly Therapeutics collaborates strategically with major pharmaceutical companies, including Celgene Corporation and Merck, to advance its research and development efforts. The company's scientific founders are recognized leaders in cancer biology and immunology, driving its mission to harness the immune system's potential for breakthrough cancer treatments.